Reports Q2 revenue $1.59B, consensus $1.56B. “During the quarter we paid down principal on our long-term debt and began implementing meaningful cost savings, which together set us on a path to achieve net leverage below 4.0x by the end of this year. We will aim to drive further improvement, with the goal of achieving net leverage of 3.5x or below by the end of 2026,” said Kevin Ali, Organon’s (OGN) CEO. “We are right where we want to be with VTAMA, making significant progress on our access objectives, with the overall portfolio compensating well for the loss of exclusivity of Atozet in Europe.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon announces American Academy of Dermatology recommendation for Vtama cream
- Morning Movers: Tesla higher following Q2 delivery figures
- Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program
- OGN Lawsuit Alert! Class Action Lawsuit Against Organon & Co.
- Organon Concludes Annual Meeting with Key Decisions